ArticleBritish journal of cancer2012
Comparison and combination of blood-based inflammatory markers with faecal occult blood tests for non-invasive colorectal cancer screening.
Article in British journal of cancer, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 3 syntheses or guidelines pooled it, 53 citations in OpenAlex.
- Where do we stand with screening for colorectal cancer and advanced adenoma based on serum protein biomarkers? A systematic review.Molecular oncology · 2024Pooled it
- Stage-Specific Sensitivity of Fecal Immunochemical Tests for Detecting Colorectal Cancer: Systematic Review and Meta-Analysis.The American journal of gastroenterology · 2020Pooled it
- TIMP-1 is a novel serum biomarker for the diagnosis of colorectal cancer: A meta-analysis.PloS one · 2018Pooled it
- Serum sCD26 for colorectal cancer screening in family-risk individuals: comparison with faecal immunochemical test.British journal of cancer · 2015Trial
- Biomarkers of inflammation and colorectal cancer risk.Frontiers in oncology · 2025Review
- Urinary dipeptidase 1 and trefoil factor 1 are promising biomarkers for early diagnosis of colorectal cancer.Journal of gastroenterology · 2024Article
- Novel biomarkers for neoplastic progression from ulcerative colitis to colorectal cancer: a systems biology approach.Scientific reports · 2023Article
- Validation of a genotype-based algorithm that identifies individuals with low, intermediate, and high serum CA19-9 levels in cancer-free individuals and in patients with colorectal cancer.Journal of gastrointestinal oncology · 2022Article
- Clinical significance of golgi protein-73 as a diagnostic marker for Egyptian patients with colorectal cancer: Preliminary study.Cancer reports (Hoboken, N.J.) · 2021Article
- Review
- Article
- Fecal Immunochemical Tests Detect Screening Participants with Multiple Advanced Adenomas Better than T1 Colorectal Cancers.Cancers · 2021Article
- The Value of Multi-targeted Fecal DNA Methylation Detection for Colorectal Cancer Screening in a Chinese Population.Journal of Cancer · 2021Article
- Blood-derived DNA methylation predictors of mortality discriminate tumor and healthy tissue in multiple organs.Molecular oncology · 2020Article
- Colorectal cancer is associated with increased circulating lipopolysaccharide, inflammation and hypercoagulability.Scientific reports · 2020Article
- Article
- Fecal immunochemical tests in combination with blood tests for colorectal cancer and advanced adenoma detection-systematic review.United European gastroenterology journal · 2018Review
- A novel multiplex detection array revealed systemic complement activation in oral squamous cell carcinoma.Oncotarget · 2018Article
- Pretreatment hematologic markers as prognostic predictors of gastroenteropancreatic neuroendocrine tumors: a systematic review and meta-analysis.OncoTargets and therapy · 2018Article
- Risk-adjusted colorectal cancer screening using the FIT and routine screening data: development of a risk prediction model.British journal of cancer · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundFaecal occult blood tests (FOBTs) are widely used for colorectal cancer (CRC) screening. Blood-based inflammatory markers have been suggested as alternative or supplementary non-invasive CRC screening tests.
methodsAmong 179 CRC patients, 193 people with advanced adenoma and 225 people free of neoplasm, C-reactive protein (CRP), serum CD26 (sCD26), complement C3a anaphylatoxin and tissue inhibitor of metalloproteinases 1 (TIMP-1) levels in blood were measured by ELISA tests, and an immunochemical FOBT (iFOBT) and a guaiac-based FOBT were performed. Receiver operating characteristic curves were constructed and the areas under the curves (AUCs) were compared.
resultsThe blood levels of CRP, sCD26 and TIMP-1 showed statistically significant differences between CRC patients and neoplasm-free participants, and levels of TIMP-1 were furthermore significantly elevated in advanced adenoma patients. For the four inflammatory markers, AUCs ranged from 0.52 to 0.62 for CRC detection and from 0.50 to 0.58 for advanced adenomas detection, compared with AUCs of 0.90 and 0.68 for the iFOBT. At 97% specificity, blood markers showed much lower sensitivities than FOBTs. Combining inflammatory markers with the iFOBT increased the AUC for advanced adenomas.
conclusionThese blood-based markers do not seem to be an alternative to FOBT-based CRC screening. The potential use of these and other blood-based tests in combination with iFOBT might deserve further attention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.